Amplifying The Vaccines Of Tomorrow
AdJane is advancing next-generation vaccines and adjuvants to combat critical global health challenges. Discover our platform.
About Us
AdJane is a clinical-stage biotechnology company advancing our proprietary OMV-VaccTM platform, designed to leverage the body’s natural immune response. As pioneers in the field of engineered Outer Membrane Vesicles (OMVs) derived from Neisseria meningitidis, our lead programs target high-burden, under-served infectious diseases with significant global health impact.
Founded to address a long-standing limitation in vaccinology, we move beyond reliance on aluminum-based adjuvants and develop vaccines rooted in decades of expertise. As a female-led company, we are setting a new standard in the industry beyond scientific innovation.
OMV-Vacc
Our proprietary vaccine platform technology
As specialists in engineered OMVs, immune-stimulating nanoparticles with intrinsic adjuvanticity, we have developed our modular OMV-Vacc platform for antigen delivery, enabling the design of next-generation vaccines.
Pipeline
Our OMVs have demonstrated an excellent safety profile in Phase I Clinical Trials, are administration-route agnostic, scalable and stable over years. See our diversified pipeline of high impact programs for more information.
ADA
Clinically Validated Adjuvant
BEA
Engineered Meningococcal OMV Vaccine for Broad Gonorrhea Protection
CARA
Best-In-Class Quadrivalent HFMD Vaccine